Trial Profile
Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Galinpepimut S (Primary) ; Montanide ISA-51; Sargramostim
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- 08 Aug 2017 According to a joint media release by Galena Biopharma Inc. and SELLAS Life Sciences Group Ltd., status changed from active, no longer recruiting to completed.
- 04 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 04 Jan 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2017.